Corbus Pharmaceuticals Reports 2017 Third Quarter Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
27
Corbus Pharmaceuticals Reports 2017 Third Quarter Financial Results and Highlights Recent Corporate and Clinical Advancements

NORWOOD, MA --(Marketwired - November 08, 2017) -

  • Positive data from three consecutive Phase 2 studies in rare and serious chronic inflammatory and fibrotic diseases provides validation of anabasum's unique activity of resolving inflammation and halting fibrosis without immunosuppression
  • Company on track to commence Phase 3 study in systemic sclerosis, Phase 2b study in cystic fibrosis and Phase 2 study in systemic lupus erythematosus before year end
  • Recent public offering completed raising approximately $32.5 million in gross proceeds extends expected cash runway into Q4 2019

Corbus Pharmaceuticals Holdings, Inc. ( NASDAQ : CRBP ) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today its financial results for the third quarter ended September 30, 2017.

The Company also provided an update on its corporate progress, clinical status and anticipated milestones for anabasum , its novel synthetic oral endocannabinoid-mimetic drug that is designed to resolve chronic inflammation and halt fibrosis in rare autoimmune inflammatory diseases.

Recent Clinical and Corporate Achievements

  • Reported positive, statistically significant 6-month clinical data from the ongoing open-label extension ("OLE") study in systemic sclerosis ("SSc") which is a continuation of the positive double-blind placebo-controlled Phase 2 study reported in November 2016;
  • Reported positive, statistically significant Phase 2 results from the double-blind, randomized, placebo-controlled trial in dermatomyositis ("DM"), a rare autoimmune disease;
  • Raised $32.5 million in gross proceeds from a secondary public offering;
  • Appointed Mr. Paris Panayiotopoulos to Board of Directors; and
  • Awarded U.S. Patent covering the use of pharmaceutical compositions comprising anabasum for treatment of rare autoimmune, inflammatory diseases through 2034.

"We are very proud that in less than four years we have successfully executed our clinical development and corporate strategy enabling us to be in position to launch our first Phase 3 late-stage study. Over the past 12 months, we have reported positive Phase 2 clinical data in succession in three distinct rare diseases with significant morbidity and mortality and that, combined, affect over 200,000 individuals in the US and EU," stated Yuval Cohen, Ph.D., Chief Executive Officer of the Company . "This important progress has positioned us for the solid implementation and execution of our four clinical studies in systemic sclerosis, cystic fibrosis, dermatomyositis and lupus. We are looking ahead to an exciting 2018."

Systemic Sclerosis Clinical Program Update

On November 5, 2017 at the American College of Rheumatology ("ACR") Annual Meeting, Corbus presented 6-month data from the on-going OLE study in systemic sclerosis . Thirty-six subjects are participating in the ongoing OLE which followed the conclusion of the 16-week double blind placebo controlled study. Subjects continued to improve in multiple clinical endpoints including a mean improvement in the modified Rodnan Skin Score (mRSS) of -8.4 points (p < 0.0001) from baseline at the start of the Phase 2 double blind placebo controlled portion of the study. 75% of subjects achieved a degree of improvement in mRSS (reduction ≥ 5 points and > 25% baseline) that has been associated with improved survival and exceeds that previously reported in other clinical trials or registries in systemic sclerosis. A third of the subjects reached a low mRSS ≤ 10 points. The ACR Composite Response Index in diffuse cutaneous systemic sclerosis score (ACR CRISS) continued to increase steadily with anabasum treatment and reached 71% (median) from study start. The speed and degree of improvement in multiple efficacy outcomes exceeds that previously reported in other clinical studies or registries in systemic sclerosis. To access the open label data and other five posters presented at ACR please click here .

Corbus is on track to commence a Phase 3 study of anabasum for the treatment of systemic sclerosis with the mRSS as the primary endpoint before year end and expects to report topline results before the end of 2019.

Systemic sclerosis is a chronic, systemic autoimmune rheumatic rare disease with an unclear etiology that affects approximately 90,000 people in the United States and Europe, with disease onset typically in mid-life and lung fibrosis resulting in a 10-year mortality rate of 40-60%. Currently, there are no FDA-approved treatments specifically indicated for the treatment of SSc, other than pulmonary artery hypertension secondary to connective tissue diseases such as SSc.

Anabasum has been granted Orphan Drug Designation and Fast Track status for the treatment of systemic sclerosis from the FDA and Orphan Designation from the EMA.

Expected Near-Term Milestones:

  • Commence Phase 3 systemic sclerosis study by end of 2017; and
  • Report 12-month data from the on-going OLE study in mid-2018.

Cystic Fibrosis ("CF") Clinical Program Update

In March 2017, Corbus reported positive topline data from the double-blind, randomized, placebo-controlled Phase 2 study of anabasum for the treatment of CF showing that anabasum, compared to placebo, reduced the rate of pulmonary exacerbations, reduced multiple inflammatory biomarkers and had an acceptable safety and tolerability profile. The 16-week study was an international, multi-center study supported by a $5 million Development Award from Cystic Fibrosis Foundation Therapeutics, Inc. Data from this study was presented at the European Cystic Fibrosis Society ("ECFS") conference in June 2017 and was also recently presented at the North American Cystic Fibrosis Conference ("NACFC"). To access the posters presented at NACFC, please click here .

Cystic fibrosis is a chronic, life-threatening, genetic rare disease, characterized by chronic lung inflammation that leads to lung damage and fibrosis that affects approximately 30,000 patients in the U.S and 75,000 patients worldwide. The current average life expectancy for CF patients is 40 years. The harmful inflammation and accompanying fibrosis in CF damages multiple organs, impairs organ function, reduces health-related quality of life, and is the most common cause of mortality. There remains a recognized unmet need for safe and effective drugs that target chronic inflammation and fibrosis for the treatment of CF without the risk of immunosuppression currently associated with existing anti-inflammatory drugs.

Anabasum has been granted Orphan Drug Designation and Fast Track status for the treatment of CF by the FDA and Orphan Designation from the EMA.

Expected Near-Term Milestones:

  • Obtain guidance from the FDA on the protocol design for the Phase 2b CF study;
  • Submit Pediatric Investigational Plan to EMA; and
  • Commence Phase 2b clinical study by end of 2017.

Dermatomyositis Clinical Program Update

In October 2017, Corbus announced positive topline results from its Phase 2 study evaluating anabasum for the treatment of skin-predominant dermatomyositis, demonstrating medically and statistically significant improvement in the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), the primary endpoint in the study. Improvements in multiple secondary patient-reported outcomes, including a number that achieved statistical significance, reinforce the signal of activity of anabasum in dermatomyositis.

Detailed Phase 2 results of safety and primary and secondary efficacy assessments were presented in a late-breaking poster presentation at the ACR Annual Meeting. Demographics and baseline characteristics of subjects were also presented in a second poster presentation. To access the ACR posters please click here .

Dermatomyositis is a rare and serious systemic autoimmune condition characterized by skin and muscle inflammation that affects as many as 70,000 people in the US. Mortality is high with 5-year survival of 70% and 10-year survival of 57%. Current standard of care includes antimalarial drugs and potent immunosuppressive agents, which often lead to significant adverse effects.

Expected Near-Term Milestones:

  • Engage regulatory authorities to review Phase 2 dermatomyositis data and determine next steps in clinical development plan; and
  • Report on six-month data from Phase 2 open-label extension study in mid-2018.

Systemic Lupus Erythematosus Clinical Program Update

Systemic lupus erythematosus ("SLE") is a prototypical autoimmune disease in which the innate immune system is chronically activated by immune complexes containing autoantibodies and self-antigens, which leads to widespread inflammation and tissue damage. According to the CDC, SLE affects between 161,000 - 322,000 people in the United States and has many manifestations, including arthritis, rash, photosensitivity, oral ulcers, pleuritis, pericarditis, kidney problems, seizures and psychosis and blood cell abnormalities. Current drugs specifically approved by the FDA for SLE are limited to aspirin, corticosteroids, hydroxychloroquine and belimumab. Physicians commonly treat disease manifestations with immunosuppressive or corticosteroid therapies that have significant toxicities.

Corbus expects that its Phase 2 clinical study evaluating anabasum for the treatment of systemic lupus erythematosus, which is being funded by the National Institute of Health, will commence before the end of 2017.

Summary of Financial Results for Third Quarter 2017

For the three months ended September 30, 2017, the Company reported a net loss of approximately $6,966,000, or a net loss per diluted share of $0.14, compared to a net loss of approximately $5,347,000, or a net loss per diluted share of $0.12 for the quarter ended September 30, 2016.

For the nine months ended September 30, 2017, the Company reported a net loss of approximately $21,728,000, or a net loss per diluted share of $0.44, compared to a net loss of approximately $12,428,000, or a net loss per diluted share of $0.31, for the nine months ended September 30, 2016.

For the three months ended September 30, 2017, operating expenses increased by approximately $1.7 million to $7.8 million due to increased spending for clinical studies, manufacturing costs to produce anabasum for clinical studies, stock compensation expense and staffing costs.

The Company ended the third quarter with approximately $36.6 million of cash and cash equivalents. On October 26, 2017, the Company completed a public offering raising approximately $32.5 million of gross proceeds. The Company expects the current cash on hand to fund operations into the fourth quarter of 2019, based on current planned expenditures.

About Anabasum

Anabasum is a synthetic oral endocannabinoid-mimetic drug that preferentially binds to cannabinoid receptor type 2 (CB2) expressed on activated immune cells and fibroblasts. CB2 activation triggers physiologic pathways that resolve inflammation, speed bacterial clearance and halt fibrosis. Nonclinical and human clinical studies to date have shown anabasum has favorable safety, tolerability and pharmacokinetic profiles. It has also demonstrated promising potency in nonclinical models of inflammation and fibrosis. Anabasum is designed to trigger the production of "Specialized Pro-resolving Lipid Mediators" that activate an endogenous cascade responsible for the resolution of inflammation and fibrosis, while reducing production of multiple inflammatory mediators. Anabasum also is designed to have a direct effect on fibroblasts to halt tissue scarring. In effect, anabasum is believed to trigger endogenous pathways to turn "off" chronic inflammation and fibrotic processes without causing immunosuppression.

About Corbus

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, anabasum, is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Anabasum has generated positive data in three Phase 2 studies in diffuse cutaneous systemic sclerosis, cystic fibrosis and dermatomyositis. Additionally, the Company is evaluating anabasum in open-label extension studies in systemic sclerosis and skin-predominant dermatomyositis. The Company expects to commence a Phase 2 study in systemic lupus erythematosus, a Phase 3 study in systemic sclerosis and a Phase 2b study in cystic fibrosis in the fourth quarter of 2017.

For more information, please visit www.CorbusPharma.com and connect with the Company on Twitter , LinkedIn , Google+ and Facebook .

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Corbus Pharmaceuticals Holdings, Inc. Condensed Consolidated Statements of Operations (Unaudited)

         
    For the Three Months Ended   For the Nine Months Ended
    September 30,   September 30,
    2017   2016   2017   2016
Collaboration revenue   $ 796,312     $ 742,558     $ 2,440,195     $ 1,535,754  
Operating expenses:                                
  Research and development     5,622,511       4,315,632       17,752,283       10,056,568  
  General and administrative     2,130,587       1,760,696       6,388,802       3,891,810  
    Total operating expenses     7,753,098       6,076,328       24,141,085       13,948,378  
Operating loss     (6,956,786 )     (5,333,770 )     (21,700,890 )     (12,412,624 )
Other income (expense), net:                                
  Interest income, net     43,402       1,731       50,039       420  
  Foreign currency exchange loss     (52,212 )     (14,729 )     (77,071 )     (16,196 )
    Other expense, net     (8,810 )     (12,998 )     (27,032 )     (15,776 )
Net loss   $ (6,965,596 )   $ (5,346,768 )   $ (21,727,922 )   $ (12,428,400 )
Net loss per share, basic and diluted   $ (0.14 )   $ (0.12 )   $ (0.44 )   $ (0.31 )
Weighted average number of common shares outstanding, basic and diluted     50,221,597       43,783,504       48,946,335       40,059,364  
                                 

Corbus Pharmaceuticals Holdings, Inc. Condensed Consolidated Balance Sheets

         
    September 30, 2017   December 31, 2016
    (Unaudited)    
ASSETS        
Current assets:        
  Cash and cash equivalents   $ 36,597,469     $ 14,992,257  
  Restricted cash     200,000       150,000  
  Grants receivable     500,000       1,000,000  
  Stock subscriptions receivable     -       330,413  
  Prepaid expenses and other current assets     719,868       930,261  
    Total current assets     38,017,337       17,402,931  
Restricted cash     -       50,000  
Property and equipment, net     337,297       435,251  
Other assets     65,026       -  
      Total assets   $ 38,419,660     $ 17,888,182  
LIABILITIES AND STOCKHOLDERS' EQUITY                
Current liabilities:                
  Notes payable   $ -     $ 271,757  
  Accounts payable     3,776,516       3,419,921  
  Accrued expenses     2,558,602       3,256,455  
  Deferred revenue     -       1,940,195  
  Deferred rent, current     -       10,263  
    Total current liabilities     6,335,118       8,898,591  
Deferred rent, noncurrent     102,561       65,724  
Other liabilities     1,482       4,632  
      Total liabilities     6,439,161       8,968,947  
Commitments and Contingencies                
Stockholders' equity                
  Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding at September 30, 2017 and December 31, 2016     -       -  
  Common stock, $0.0001 par value; 150,000,000 shares authorized, 50,223,010 and 44,681,745 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively     5,022       4,468  
  Additional paid-in capital     86,979,888       42,191,256  
  Accumulated deficit     (55,004,411 )     (33,276,489 )
    Total stockholders' equity     31,980,499       8,919,235  
      Total liabilities and stockholders' equity   $ 38,419,660     $ 17,888,182  

Investor Contact Jenene Thomas Jenene Thomas Communications, LLC Phone: (908) 938-1475 Email: jenene@jenenethomascommunications.com Media Contact Nic DiBella JPA Health Communications Phone: (617) 657-1307 Email: Nic@jpa.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 61

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Dallas College Recognition Signals Workforce Value

Updated Category News Views 49

Economic mobility rarely arrives with brass bands, but it can show up in a community-college ranking. Dallas College has landed on TIME and Statista's inaugural America’s Best Community Colleges 2027 list, one of 250 schools selected from roughly 1,100 nationwide. For a region that keeps talking about talent pipelines, this is a useful piece of outside validation—not...

Continue Reading
Align Wagner Collection Tests Men's Footwear Depth

Updated Category News Views 57

Three pairs of shoes are not a revolution, but they can expose whether a young brand has its footing. Align, established in 2025 by H.H. Brown, is rolling out the Wagner collection for Fall-Winter 2026 with a waterproof boot, a penny loafer and a lace-up oxford. That is a sensible little arsenal, not some overstuffed catalog dreamed up by a marketing committee that has...

Continue Reading
Lennar's 6.73% Slide Puts Disclosure Claims in Focus

Updated Category News Views 12

A homebuilder can survive ugly margins; murky demand signals are another beast entirely. Lennar is staring at a securities class action after a bruising run of disclosures and market reactions, and the central issue is not whether housing got tougher. Everybody with a pulse knew rates were squeezing buyers. The issue is whether NYSE:LEN gave investors a sufficiently clear...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 82

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 78

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 80

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
Nansha's Trade Pitch Has Numbers, but Questions Remain

Updated Category News Views 84

A Chilean cherry spending 22 days at sea can tell an investor plenty about where Guangzhou's Nansha District wants to sit in Asia-Pacific commerce. Not glamorous, no. But trade infrastructure rarely is until volumes pile up, routes deepen, and somebody else finds they cannot easily replicate the network. Nansha is using the expected 33rd APEC Economic Leaders' Meeting in...

Continue Reading
Mason Adds Nonprofit Expertise to Institutional Bench

Updated Category News Views 110

Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 100

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading

Top 5 Most Recently Viewed Articles

DatChat Receives Mexican Patent for Enhanced Privacy Solutions

Updated Category News Views 157

DatChat's Latest Patent Achievement New Brunswick, NJ - DatChat, Inc. (NASDAQ: DATS), a leading company in secure messaging and social media, has exciting news to share. Recently, the Mexican Patent office issued a Notice of Allowance for DatChat's patent application titled "Systems and Methods of Transforming Electronic Content." This development follows the company...

Continue Reading
Flora Growth Partners with Canopy to Enhance Cannabis Access

Updated Category News Views 111

Flora Growth Enters the Australian Medical Cannabis Market Flora Growth Corp (NASDAQ: FLGC) has recently taken a significant step into the Australian medical cannabis arena through its strategic partnership with Canopy Growth Corp (NASDAQ: CGC). A distribution agreement has been signed, allowing Flora's subsidiary, Australian Vaporizers, to handle the distribution of...

Continue Reading
Digital Brands Group Sets Public Offering of 11.36 Million Units

Updated Category News Views 167

Digital Brands Group Projects Strong Growth with New Offering Digital Brands Group, Inc. (OTC PINK: DBGI), a unique entity known for curating luxury lifestyle brands, has recently made headlines with their announcement regarding a public offering. This initiative, which involves an impressive volume of 11.36 million units, is set to make waves in the market. Details of...

Continue Reading
Unraveling Solana's Remarkable Rise From $11 to $166

Updated Category News Views 154

Unraveling Solana's Remarkable Rise From $11 to $166 Solana (SOL), a cryptocurrency that emerged in March 2020, has astonished investors with its dramatic increase in value. It has risen more than 15 times its initial value, predominantly bolstered by a vibrant ecosystem that has flourished around various meme coins. Jim Cramer’s Warning In 2022, Jim Cramer, a prominent...

Continue Reading
LO3 Capital Revolutionizes Travel Services with CCRA Deal

Updated Category News Views 189

LO3 Capital Makes Strategic Investment in CCRA International LO3 Capital, a dynamic private investment firm, is making waves with its recent senior debt investment in CCRA International, Inc. This relationship is pivotal for CCRA, a technology-driven travel services platform, as it progresses towards acquiring ABC Global Services. This acquisition is set to form one of...

Continue Reading